Novo’s $3.3bn GalXC quest
The usually conservative group spends big on Dicerna – but others might be interested too.
Biopharma throws grease on the deal wheels
Company takeovers with promises of more cash down the road ticked up this year, a new Evaluate Vantage analysis finds.
Key third-quarter readouts for big pharma
Abbvie expects more Rinvoq data in ulcerative colitis while Astrazeneca takes on myasthenia gravis, and gene therapy is in play for Pfizer and Roche.
Bristol’s buy moves it to the top of the sales charts
The addition of Celgene made Bristol’s sales team pharma’s most productive last year on one measure, but the accolade might be short-lived.
Quiet times return for biopharma takeouts
The first quarter of 2021 saw fewer deals than any in recent memory.
Fresh antitrust push hits biopharma
Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.
